Home/Filings/4/0000921895-20-002557
4//SEC Filing

Graham Camilla 4

Accession 0000921895-20-002557

CIK 0001599298other

Filed

Oct 6, 8:00 PM ET

Accepted

Oct 7, 7:47 PM ET

Size

5.7 KB

Accession

0000921895-20-002557

Insider Transaction Report

Form 4
Period: 2020-10-04
Graham Camilla
Chief Clinical Affairs Officer
Transactions
  • Award

    Stock Option (right to buy)

    2020-10-04$3.34/sh+400,000$1,336,000400,000 total
    Exercise: $3.34Exp: 2030-10-04Common Stock (400,000 underlying)
Footnotes (1)
  • [F1]The option was granted on October 4, 2020 pursuant to the Company's 2020 Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 4, 2021, subject to the satisfaction of certain performance targets.

Issuer

Summit Therapeutics Inc.

CIK 0001599298

Entity typeother

Related Parties

1
  • filerCIK 0001827543

Filing Metadata

Form type
4
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 7:47 PM ET
Size
5.7 KB